U.S. Markets closed

CytoSorbents To Start US Study With CytoSorb For Ticagrelor Removal

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • The FDA has signed off conditional approval for the STAR-T study to assess CytoSorbents Corporation's (NASDAQ: CTSO) blood purification device, CytoSorb, to remove Ticagrelor.

  • The company can now initiate clinical trial agreement negotiations and institutional review board submissions.

  • The randomized, controlled clinical trial was designed to support U.S. marketing submission for CytoSorb, to remove AstraZeneca Plc's (NASDAQ: AZN) Brilinta (ticagrelor) during the cardiothoracic surgery to reduce perioperative bleeding complications.

  • Ticagrelor is one of the most commonly used blood thinners to reduce the risk of cardiac death, heart attacks, and strokes in patients with the acute coronary syndrome.

  • It is also used to reduce the rate of stent thrombosis in patients who have been stented.

  • However, when patients on ticagrelor require emergent cardiac surgery, the risk of severe bleeding and complications is very high.

  • Last year in January, CytoSorb scored approval in the E.U. to remove ticagrelor during surgery requiring cardiopulmonary bypass.

  • In April 2020, CytoSorb received FDA Breakthrough Designation to remove ticagrelor in a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.

  • Price Action: CTSO shares are down 2.2% at $8.8 in market trading hours on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.